Dare Bioscience, Inc. 8-K

What Happened

• Daré Bioscience, Inc. announced it completed the closing of its Regulation A offering on April 17, 2026. The company issued 20,000 Investor Units; each unit consisted of one share of Series A Convertible Preferred Stock and two warrants (Investor Warrants) to purchase one share of common stock each.
• The Investor Units were offered at $5.00 per unit. In this closing Daré issued 20,000 shares of Series A Preferred Stock and Investor Warrants to purchase up to 40,000 shares of common stock, raising $100,000 in gross proceeds. The offering is being conducted under a Form 1-A (File No. 024-12688) that was qualified by the SEC on April 1, 2026. Terms were previously described in Daré’s Form 8-K filed January 29, 2026.

Key Details

• Closing date: April 17, 2026.
• Units issued: 20,000 Investor Units (20,000 Series A Preferred shares + warrants for up to 40,000 common shares).
• Price per unit: $5.00; gross proceeds from this issuance: $100,000.
• Offering vehicle: Regulation A offering under Form 1-A (qualified April 1, 2026); additional terms previously disclosed in Jan 29, 2026 Form 8-K.

Why It Matters

• Capital and dilution: The company received $100,000 from this closing, and holders of the Series A Preferred and the Investor Warrants could increase the number of outstanding common shares if those securities convert or are exercised (potentially up to 40,000 common shares from the warrants issued at this closing).
• Transparency: The filing informs investors of recent changes to the company’s capital structure and references the Form 1‑A offering materials for details on conversion and exercise mechanics. Investors should review the offering circular and prior 8-K for the full terms and any potential impact on share count and voting/financial rights.